Clinical Trials
10
Active:0
Completed:0
Trial Phases
2 Phases
Phase 2:7
Phase 4:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (10 trials with phase data)β’ Click on a phase to view related trials
Phase 2
7 (70.0%)Phase 4
3 (30.0%)p53 Gene Therapy in Treatment of Diabetes Concurrent With Hepatocellular Carcinoma
Phase 2
- Conditions
- DiabetesHCC
- Interventions
- Drug: p53 gene therapyDrug: Trans-catheter embolization
- First Posted Date
- 2015-09-28
- Last Posted Date
- 2015-09-28
- Lead Sponsor
- Shenzhen SiBiono GeneTech Co.,Ltd
- Target Recruit Count
- 40
- Registration Number
- NCT02561546
- Locations
- π¨π³
first affiliated hospital in Dalian University, Dalian, Liaoning, China
Trans-catheter Arterial Embolization Combined With p53 Gene Therapy for Treatment of Advanced Hepatocellular Carcinoma
Phase 2
- Conditions
- Advanced Hepatocellular Carcinoma (HCC)
- Interventions
- Drug: TAE plus P53 geneOther: TAE
- First Posted Date
- 2015-07-27
- Last Posted Date
- 2015-07-27
- Lead Sponsor
- Shenzhen SiBiono GeneTech Co.,Ltd
- Target Recruit Count
- 60
- Registration Number
- NCT02509169
- Locations
- π¨π³
first affiliated hospital in Dalian University, Dalian, Liaoning, China
p53 Gene in Treatment of Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer
Phase 2
- Conditions
- Ovarian Epithelial CancerFallopian Tube CancerPrimary Peritoneal Cancer
- Interventions
- First Posted Date
- 2015-05-06
- Last Posted Date
- 2015-05-06
- Lead Sponsor
- Shenzhen SiBiono GeneTech Co.,Ltd
- Target Recruit Count
- 100
- Registration Number
- NCT02435186
- Locations
- π¨π³
xijing hospital in China Medical University, Shenyang, Liaoning, China
P53 Gene Combined With Radio- and Chemo-therapy in Treatment of Unresectable Locally Advanced Head and Neck Cancer
Phase 2
- Conditions
- Advanced Head and Neck Cancer
- Interventions
- First Posted Date
- 2015-04-29
- Last Posted Date
- 2015-04-29
- Lead Sponsor
- Shenzhen SiBiono GeneTech Co.,Ltd
- Target Recruit Count
- 60
- Registration Number
- NCT02429037
- Locations
- π¨π³
Jiangsu cancer hospital, Nanjing, Jiangsu, China
Recombinant Adenoviral Human p53 Gene in Treatment of Malignant Pleural Effusion
Phase 2
- Conditions
- Malignant Pleural Effusion
- Interventions
- First Posted Date
- 2015-04-29
- Last Posted Date
- 2015-04-29
- Lead Sponsor
- Shenzhen SiBiono GeneTech Co.,Ltd
- Target Recruit Count
- 90
- Registration Number
- NCT02429726
- Locations
- π¨π³
The First Affiliated Hospital of Xi'an Jiao Tong University, Xian, Shanxi, China
- Prev
- 1
- 2
- Next
News
No news found